Showing results (601-610 of 1,025) with videos related to

Sort By:
Pageof 103
British Journal of Pharmacology|March 2, 1999
A comparison of an A1 adenosine receptor agonist (CVT-510) with diltiazem for slowing of AV nodal conduction in guinea-pigS Snowdy, H X Liang, B Blackburn, et al.
Aquatic Toxicology (Amsterdam, Netherlands)|June 17, 2023
Scoping intergenerational effects of nanoplastic on the lipid reserves of Antarctic krill embryosEmily Rowlands, Tamara Galloway, Matthew Cole, et al.
Optics Letters|November 1, 2023
High-quality factor Ta2O5-on-insulator resonators with ultimate thermal stabilityJ Rasmus Bankwitz, Martin A Wolff, Adrian S Abazi, et al.
Radiology|February 23, 2011
High-grade acute organ toxicity as positive prognostic factor in adjuvant radiation and chemotherapy for locally advanced head and neck cancerHendrik A Wolff, Benjamin Daldrup, Klaus Jung, et al.
The American Journal of Clinical Nutrition|February 27, 2009
Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acidsSandra C van Calcar, Erin L MacLeod, Sally T Gleason, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|July 22, 2006
The flounder organic anion transporter fOat has sequence, function, and substrate specificity similarity to both mammalian Oat1 and Oat3Amy G Aslamkhan, Deborah M Thompson, Jennifer L Perry, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 27, 2025
Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trialStacy A Rudnicki, Paulos Gebrehiwet, Stuart Kupfer, et al.
British Journal of Cancer|June 24, 2010
Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experienceP Ströbel, R Bargou, A Wolff, et al.
Lab on a Chip|July 23, 2004
Measurements of scattered light on a microchip flow cytometer with integrated polymer based optical elementsZ Wang, J El-Ali, M Engelund, et al.
Cancer Investigation|September 18, 2008
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumorsMichael J Overman, Scott Kopetz, Gauri Varadhachary, et al.
Pageof 103